Catalog #SIM0089
InVivoSIM anti-human CD20 (Ofatumumab Biosimilar)
Clone
Ofatumumab
Reactivities
Human
Isotype
Human IgG1, κ
Product Description
This non‑therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Ofatumumab, making it ideal for research use. Ofatumumab is a fully human IgG1 monoclonal antibody that specifically targets CD20, a B cell surface antigen expressed from the pre‑B to mature B cell stage but not on plasma cells. CD20 plays a critical role in B cell development, activation, and proliferation. By binding to a unique membrane‑proximal epitope on CD20, Ofatumumab induces B cell depletion through complement‑dependent cytotoxicity (CDC) and antibody‑dependent cellular cytotoxicity (ADCC). This Ofatumumab biosimilar is well suited for studying B cell–mediated diseases, CD20 biology, and the immunologic mechanisms of B cell depletion in autoimmune disease and cancer.
Specifications
Isotype | Human IgG1, κ |
---|---|
Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
Immunogen | Human CD20 |
Reported Applications |
In vivo functional assays in vitro functional assays Flow cytometry ELISA |
Formulation |
pH 7.0 Contains no stabilizers or preservatives |
Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL gel clotting assay |
Purity |
≥95% Determined by SDS-PAGE |
Sterility | 0.2 µm filtration |
Production | Purified from cell culture supernatant in an animal-free facility |
Purification | Protein A |
Molecular Weight | 150 kDa |
Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
Need a Custom Formulation? | See All Antibody Customization Options |